Table 4.
Possible reasons for not achieving superiority
| - AFP imbalance favoring sorafenib arm |
| - Hepatitis C-related HCC imbalance favoring for sorafenib arm |
| - By excluding patients with main portal vein tumor thrombus and tumor burden ≥50%, patients were relatively good prognostic population in both arms, leading to long postprogression survival (PPS) who likely received post trial treatments |
| - OS benefit was diluted by long PPS |